Steven M. Johnson, Ph.D. - Publications

Affiliations: 
Biochemistry and Molecular Biology Indiana Univ. School of Medicine 
Area:
Chemical Biology / Medicinal Chemistry

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Connelly S, Mortenson DE, Choi S, Wilson IA, Powers ET, Kelly JW, Johnson SM. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 28625364 DOI: 10.1016/j.bmcl.2017.05.080  0.84
2016 Abdeen S, Salim N, Mammadova N, Summers CM, Frankson R, Ambrose AJ, Anderson GG, Schultz PG, Horwich AL, Chapman E, Johnson SM. GroEL/ES inhibitors as potential antibiotics. Bioorganic & Medicinal Chemistry Letters. 26: 3127-34. PMID 27184767 DOI: 10.1016/j.bmcl.2016.04.089  0.84
2015 Lee AJ, Wang G, Jiang X, Johnson SM, Hoang ET, Lanté F, Stornetta RL, Beenhakker MP, Shen Y, Julius Zhu J. Canonical Organization of Layer 1 Neuron-Led Cortical Inhibitory and Disinhibitory Interneuronal Circuits. Cerebral Cortex (New York, N.Y. : 1991). 25: 2114-26. PMID 24554728 DOI: 10.1093/cercor/bhu020  0.64
2014 Johnson SM, Sharif O, Mak PA, Wang HT, Engels IH, Brinker A, Schultz PG, Horwich AL, Chapman E. A biochemical screen for GroEL/GroES inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 786-9. PMID 24418775 DOI: 10.1016/j.bmcl.2013.12.100  0.84
2012 Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, et al. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. Journal of Medicinal Chemistry. 55: 2416-26. PMID 22320388 DOI: 10.1021/jm201713h  0.84
2012 Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. Journal of Molecular Biology. 421: 185-203. PMID 22244854 DOI: 10.1016/j.jmb.2011.12.060  0.84
2010 Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Current Opinion in Structural Biology. 20: 54-62. PMID 20133122 DOI: 10.1016/j.sbi.2009.12.009  0.84
2010 Choi S, Reixach N, Connelly S, Johnson SM, Wilson IA, Kelly JW. A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. Journal of the American Chemical Society. 132: 1359-70. PMID 20043671 DOI: 10.1021/ja908562q  0.84
2010 Johnson SM, Wiseman L, Paulsson JF, Choi S, Powers ET, Buxbaum JN, Kelly JW. Understanding and Ameliorating the TTR Amyloidoses Protein Misfolding Diseases: Current and Emerging Principles and Therapies. 967-1003. DOI: 10.1002/9780470572702.ch45  0.84
2009 Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. Journal of Medicinal Chemistry. 52: 1115-25. PMID 19191553 DOI: 10.1021/jm801347s  0.84
2008 Chapman E, Farr GW, Fenton WA, Johnson SM, Horwich AL. Requirement for binding multiple ATPs to convert a GroEL ring to the folding-active state. Proceedings of the National Academy of Sciences of the United States of America. 105: 19205-10. PMID 19050077 DOI: 10.1073/pnas.0810657105  0.84
2008 Johnson SM, Connelly S, Wilson IA, Kelly JW. Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. Journal of Medicinal Chemistry. 51: 6348-58. PMID 18811132 DOI: 10.1021/jm800435s  0.84
2008 Johnson SM, Connelly S, Wilson IA, Kelly JW. Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors. Journal of Medicinal Chemistry. 51: 260-70. PMID 18095641 DOI: 10.1021/jm0708735  0.84
2005 Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Accounts of Chemical Research. 38: 911-21. PMID 16359163 DOI: 10.1021/ar020073i  0.84
2005 Petrassi HM, Johnson SM, Purkey HE, Chiang KP, Walkup T, Jiang X, Powers ET, Kelly JW. Potent and selective structure-based dibenzofuran inhibitors of transthyretin amyloidogenesis: kinetic stabilization of the native state. Journal of the American Chemical Society. 127: 6662-71. PMID 15869287 DOI: 10.1021/ja044351f  0.84
2005 Wiseman RL, Johnson SM, Kelker MS, Foss T, Wilson IA, Kelly JW. Kinetic stabilization of an oligomeric protein by a single ligand binding event. Journal of the American Chemical Society. 127: 5540-51. PMID 15826192 DOI: 10.1021/ja042929f  0.84
2005 Johnson SM, Petrassi HM, Palaninathan SK, Mohamedmohaideen NN, Purkey HE, Nichols C, Chiang KP, Walkup T, Sacchettini JC, Sharpless KB, Kelly JW. Bisaryloxime ethers as potent inhibitors of transthyretin amyloid fibril formation. Journal of Medicinal Chemistry. 48: 1576-87. PMID 15743199 DOI: 10.1021/jm049274d  0.84
Show low-probability matches.